Hannover Medical School spinout Cardior has welcomed both new and existing backers, such as Bristol Myers Squibb, for a series B round led by Inkef Capital.

Cardior Pharmaceuticals, a Germany-based developer of therapeutics for cardiac diseases based on research at Hannover Medical School, closed a €64m ($76m) series B round today led by venture capital firm Inkef Capital.
Pharmaceutical firm Bristol Myers Squibb (BMS) took part in the round together with Fund+, Sunstone, Hadean Ventures, Coparion, LSP, BioMedPartners and High-Tech Gründerfonds (HTGF).
Founded in 2016, Cardior Pharmaceuticals is working on non-coding RNA-based therapeutics that would be capable of preventing, repairing and reversing heart diseases…

Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.